Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMENCER
NCT05692024Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2028
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Coffee with Placebo (2 arms). Primary endpoint: Change in hepatic fat fraction at 2 years. Started Mar 2024; status: recruiting.
02
Drugs
Caffeinated coffee
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05692024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692024.